Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255270 | 1.00 | ATM (0.60) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL8353576 | 0.88 | OPRK1 (0.64) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL1643093 | 0.84 | CTSK (0.66) | ATMCTSLCTSSMEN1KMT2A | |
| SCHEMBL5325864 | 0.84 | CTSK (0.66) | ATMCTSLCTSSMEN1KMT2A | |
| SCHEMBL1059174 | 0.84 | CTSK (0.66) | ATMCTSLCTSSMEN1KMT2A | |
| SCHEMBL13168601 | 0.84 | ATM (0.69) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL16215928 | 0.84 | ATM (0.69) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL5348791 | 0.82 | PPARG (0.71) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL5348787 | 0.82 | PPARG (0.71) | ATMOPRK1CTSLCTSSMEN1 | |
| SCHEMBL19017976 | 0.82 | CTSK (0.55) | CTSLCTSSMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | ATM 4261/4885OPRK1 1022/4885CTSL 4166/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | ATM 4261/4885OPRK1 1022/4885CTSL 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.